Nothing Special   »   [go: up one dir, main page]

EA202090053A3 - Способы и композиции для лечения неэффективного эритропоэза - Google Patents

Способы и композиции для лечения неэффективного эритропоэза

Info

Publication number
EA202090053A3
EA202090053A3 EA202090053A EA202090053A EA202090053A3 EA 202090053 A3 EA202090053 A3 EA 202090053A3 EA 202090053 A EA202090053 A EA 202090053A EA 202090053 A EA202090053 A EA 202090053A EA 202090053 A3 EA202090053 A3 EA 202090053A3
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
erythropoesis
compositions
effective
treating non
Prior art date
Application number
EA202090053A
Other languages
English (en)
Other versions
EA202090053A2 (ru
Inventor
Джасбир СИХРА
Роберт Скотт Пирсалл
Равиндра КУМАР
Нага Венката Саи Раджасекхар Сурагани
Original Assignee
Акселерон Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акселерон Фарма, Инк. filed Critical Акселерон Фарма, Инк.
Publication of EA202090053A2 publication Critical patent/EA202090053A2/ru
Publication of EA202090053A3 publication Critical patent/EA202090053A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам лечения неэффективного эритропоэза у пациента, включающим введение пациенту полипептида ActRIIB, по меньшей мере на 90% идентичного последовательности из 109 аминокислот SEQ ID NO: 1, где указанный полипептид содержит кислую аминокислоту в положении 79.
EA202090053A 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза EA202090053A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17

Publications (2)

Publication Number Publication Date
EA202090053A2 EA202090053A2 (ru) 2020-04-30
EA202090053A3 true EA202090053A3 (ru) 2020-06-30

Family

ID=48141315

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090053A EA202090053A3 (ru) 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза
EA201490809A EA034563B1 (ru) 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201490809A EA034563B1 (ru) 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией

Country Status (13)

Country Link
US (4) US20130243743A1 (ru)
EP (3) EP3520805B1 (ru)
JP (4) JP6092883B2 (ru)
KR (4) KR20220075438A (ru)
CN (3) CN107693776A (ru)
AU (4) AU2012326207B2 (ru)
BR (3) BR122019023166B1 (ru)
CA (1) CA2852683A1 (ru)
DK (1) DK3520805T3 (ru)
EA (2) EA202090053A3 (ru)
ES (2) ES2869168T3 (ru)
HK (3) HK1203413A1 (ru)
WO (1) WO2013059347A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN103479994B (zh) 2005-11-23 2019-08-30 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
MA39722A (fr) * 2014-03-21 2021-06-02 Acceleron Pharma Inc Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
ES2845650T3 (es) * 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
PL3286206T3 (pl) 2015-04-22 2021-09-13 Biogen Ma Inc. Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni
MY189601A (en) * 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps
MA42160A (fr) 2015-05-20 2018-03-28 Maria Cappellini Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US11267865B2 (en) * 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3538128A4 (en) 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
DK3638243T3 (da) * 2017-06-14 2024-10-28 Celgene Corp Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
WO2004034962A2 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
WO2010019261A1 (en) * 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20180085825A (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

Also Published As

Publication number Publication date
EA034563B1 (ru) 2020-02-20
AU2020286229A1 (en) 2021-01-07
AU2017201580A1 (en) 2017-03-30
CN103987403A (zh) 2014-08-13
EA201490809A1 (ru) 2014-09-30
ES2869168T3 (es) 2021-10-25
WO2013059347A1 (en) 2013-04-25
JP6383821B2 (ja) 2018-08-29
JP2014530253A (ja) 2014-11-17
BR122019023166B1 (pt) 2021-02-23
JP2017101060A (ja) 2017-06-08
EP2797620A1 (en) 2014-11-05
DK3520805T3 (da) 2021-04-19
BR112014009528A8 (pt) 2019-12-10
CN103987403B (zh) 2017-12-01
EP2797620A4 (en) 2015-05-20
US20170327800A1 (en) 2017-11-16
JP2020186277A (ja) 2020-11-19
EP3875104A1 (en) 2021-09-08
JP6796626B2 (ja) 2020-12-09
AU2018247262A1 (en) 2018-11-01
CN107693776A (zh) 2018-02-16
US20130243743A1 (en) 2013-09-19
EP3520805B1 (en) 2021-03-10
ES2741477T3 (es) 2020-02-11
EP3520805A1 (en) 2019-08-07
BR122019023174B1 (pt) 2021-02-23
AU2017201580B2 (en) 2018-07-12
HK1203413A1 (en) 2015-10-30
KR20200019261A (ko) 2020-02-21
AU2018247262B2 (en) 2020-12-24
CN107837390A (zh) 2018-03-27
HK1250341A1 (zh) 2018-12-14
EP2797620B1 (en) 2019-04-24
KR20190105113A (ko) 2019-09-11
US20210207107A1 (en) 2021-07-08
US20170137791A1 (en) 2017-05-18
AU2012326207B2 (en) 2016-12-15
AU2012326207A1 (en) 2014-05-15
HK1252940A1 (zh) 2019-06-06
KR102079482B1 (ko) 2020-02-19
KR20140084211A (ko) 2014-07-04
BR112014009528A2 (pt) 2017-05-09
EA202090053A2 (ru) 2020-04-30
JP2018165287A (ja) 2018-10-25
JP6092883B2 (ja) 2017-03-08
BR112014009528B1 (pt) 2020-12-29
CA2852683A1 (en) 2013-04-25
KR20220075438A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
EA202090053A3 (ru) Способы и композиции для лечения неэффективного эритропоэза
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
IN2014KN01715A (ru)
IN2014KN01713A (ru)
IN2014KN01716A (ru)
IN2014KN01714A (ru)
MX2014000373A (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b.
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
IN2014CN04498A (ru)
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
EA201391387A1 (ru) Нейропротекторные пептиды
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
NZ700467A (en) Treatments suitable for malassezia infections
BR112014018106A2 (pt) composto, uso de um composto, e, método para tratar uma doença fibrótica
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии